Filter
3462
Filtered Results: 3462
Text search:
First
line
drug
management
Featured
Recommendations
360
New Publications
1070
Language
Document type
No document type
2151
Studies & Reports
465
Guidelines
452
Manuals
158
Strategic & Response Plan
131
Training Material
51
Fact sheets
30
Situation Updates
13
Infographics
5
Resource Platforms
4
Brochures
1
Online Courses
1
Countries / Regions
India
238
Kenya
122
Global
104
South Africa
100
Ethiopia
95
Uganda
92
Nigeria
81
Western and Central Europe
74
Nepal
73
Tanzania
71
Malawi
69
Sierra Leone
67
Liberia
60
Myanmar / Burma
56
Zambia
55
Namibia
53
Bangladesh
50
Ghana
47
Rwanda
44
Africa
38
Latin America and the Carribbean
35
Eastern Europe
35
South–East Asia Region
28
Zimbabwe
27
Philippines
26
Cambodia
26
Lesotho
25
Asia
24
Ukraine
22
Botswana
18
Indonesia
17
Syria
15
Congo, Democratic Republic of
14
Senegal
13
Mozambique
13
Eswatini/ Swaziland
12
Cameroon
11
Burkina Faso
11
East and Southern Africa
10
Eastern Europe and Central Asia
9
Tajikistan
8
Colombia
8
Russia
8
Pakistan
8
Albania
7
Haiti
7
West and Central Africa
7
Vietnam
7
South Sudan
7
Thailand
6
Benin
6
Afghanistan
6
Guinea
6
USA
6
Western Pacific Region
6
Sudan
6
Laos
5
Venezuela
5
Brazil
5
Moldova
5
Georgia
5
Iraq
5
Timor Leste/ East Timor
4
Turkey
4
China
4
Germany
4
Middle East and North Africa
4
United Kingdom
4
Sri Lanka
4
North Macedonia
3
Mexico
3
El Salvador
3
Iran
3
Fiji
3
Peru
3
Jordan
3
North America
3
Argentina
3
Lebanon
3
Papua New Guinea
3
Central African Republic
3
Bhutan
3
Somalia
3
Armenia
2
Jamaica
2
France
2
Spain
2
Côte d’Ivoire / Ivory Coast
2
Bolivia
2
Mali
2
North Korea
1
Gambia
1
Kazakhstan
1
Chile
1
Canada
1
Estonia
1
Kyrgyzstan
1
Congo-Brazzaville
1
Niger
1
Uzbekistan
1
Morocco
1
Bulgaria
1
Lithuania
1
Saudi Arabia
1
Paraguay
1
Gabon
1
Uruguay
1
Turkmenistan
1
Denmark
1
Maldives
1
Mauritius
1
Tunisia
1
Portugal
1
Nicaragua
1
Romania
1
Greece
1
Honduras
1
Libya
1
Madagascar
1
Guatemala
1
Authors & Publishers
Publication Years
Category
Countries
1532
Clinical Guidelines
333
Public Health
167
Women & Child Health
151
Key Resources
96
Capacity Building
56
Pharmacy & Technologies
39
Toolboxes
TB
380
HIV
348
Mental Health
243
AMR
187
NTDs
111
COVID-19
100
Pharmacy
94
Caregiver
68
NCDs
62
Malaria
62
Rapid Response
48
Conflict
43
Ebola & Marburg
42
Planetary Health
35
Refugee
29
Disability
27
Global Health Education
27
Health Financing Toolbox
24
Natural Hazards
18
Polio
16
Cholera
14
Zika
9
Specific Hazards
8
Social Ethics
4
2.0 Rapid Response
4
This National Action Plan addresses actions needed to be taken in order to combat antimicrobial resistance (AMR) in the country. It is obligatory to raise awareness of antimicrobial resistance and promote behavioral change through public communication
programmes that targets human, animal and plant...
The NDMS&IP focuses on mainstreaming disability to promote equitable access to services in the six thematic areas of health, education, livelihoods, empowerment, and social inclusion and cross-cutting issues.
The first part of the NDMS&IP outlines incongruences between national and sectoral policie...
In case of resistance to rifampicin, fluoroquinolones become the preferred category of second-line drugs. Unfortunately, quinolone-resistant strains of Mycobacterium leprae have also been reported in several countries, probably due to the extensive use of quinolones for treating several types of inf...
Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...
People affected by impairments and disabilities associated with TB are even more likely to belong to marginalized segments of society and are more likely to have their human rights unprotected. The challenges faced by people affected by TB include the consequences of impairment and disability associ...
This booklet is recommended for all health workers who diagnose and treat leprosy, especially those at the first referral level such as a health centre. It contains more detail than the WHO Guide to Eliminate Leprosy as a Public Health Problem. The Guide gives practical advice on how to diagnose lep...
The Democratic Republic of Timor-Leste has the highest TB incidence rate in the South East Asian Region - 498 per 100,000, which is the seventh highest in the world. In Timor-Leste TB is the eighth most common cause of death.
The salient observations are as follows:
In 2018, 487 (12.5%) of the...
There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the drug development process towards important regi...
The main objective of these guidelines is to provide guidance on up-to-date, uniform, evidence-informed practices for suspecting, diagnosing and managing various forms of extra-pulmonary tuberculosis (EPTB) at all levels of healthcare delivery. They can then contribute to the National Programme to i...
Despite the considerable improvement in global health, millions of people still lack access to quality health services, including access to effective antimicrobial medicines, or are impoverished as a result of health spending. At the same time, antimicrobial resistance – a consequence of overuse a...
The recommendations cover the level of blood pressure to start medication, what type of medicine or combination of medicines to use, the target blood pressure level, and how often to have follow-up checks on blood pressure. In addition, the guideline provides the basis for how physicians and other h...
2nd edition. These guidelines include several notable changes from the first edition. For cutaneous leishmaniasis, ketoconazole has been removed from the list of treatment options; the number of Leishmania species for which there is strong evidence for the efficacy of miltefosine has increased from ...
Version 10.1_5 October 2020
These Guidelines are available in different formats: As a paper booklet, a PDF, a mobile app, and now also as a website.
The 2019 version of the Guidelines introduces a new drug-drug interaction panel and now consists of six main sections, including a general overview ...
Review over the work and challenges of the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC) in combatting counterfeiting of medicines in Nigeria.
Namibia is estimated to be at 94-97-93 as defined by the UNAIDS 95-95-95 treatment cascade, one of the first high burden countries to approach epidemic control. COP22 is about sustaining the impact of years of investment and partnership with the Namibian government and other stakeholders by employin...
The National Strategic Plan on Malaria Prevention and Elimination Period 2021 – 2025 seeks to build on the previous national successes of the National Institute of Malariology, Parasitology, and Entomology (NIMPE) while addressing current challenges to reduce the overall burden of malaria in the S...
The Newborn Situational Analysis reports of 2009 and 2011, as well as the “Bottleneck analysis on neonatal health” of 2013, culminated in the Nigeria launch of “Call to action on Newborn health” at the first National Newborn Health Conference in 2014. This call to action provided the framewo...
The guidelines presented in this document are designed to provide a useful resource for healthcare professionals involved in clinical case management. They were developed taking into consideration services provided at different levels within the health system and resources available. These guideline...
This document aims to provide guidance to healthcare facilities and healthcare providers in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) on preparedness and infection prevention and control (IPC) measures for the management of possible and confirmed cases of COVID-1...
To understand the national situation, Ethiopia did a situation assessment, launched its first strategy in 2011, and took action to contain AMR, as detailed in the blue boxes found throughout this strategy. This updated version of the strategy was in response to the revised health and medicines polic...
